Document:

EX-10.26

 EXHIBIT 10.26 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDMENT 

TO 
 MARKETING AUTHORIZATION HOLDER
AGREEMENT 
 (“Amendment 1”) 
 This
Amendment (“Amendment 1”) is made this 1st day of September, 2013, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom
(hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8500. Japan (hereinafter referred to as “MAH”) 

Recitals: 
 WHEREAS, MANUFACTURER and MAH are parties to
the Marketing Authorization Holder Agreement dated July 29, 2011 (“Agreement’); 
 WHEREAS, as of July 1st, 2012 (“Effective
Date”), the parties agreed to modify the Agreement to adjust the commission defined in the Agreement; and 
 WHEREAS, MANUFACTURER and MAH now wish to
memorialize the amounts to be paid by MANUFACTURER to MAH under the Agreement. 
 NOW, THEREFORE IN CONSIDERATION OF THE FOREGOING, and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged and agreed, MANUFACTURER and MAH agree to amend the Agreement as follows: 
  

	1.	This Amendment shall have effect as of the Effective Date. 

  

	2.	Appendix A of the Agreement shall be replaced by as attached hereto. The parties acknowledge and agree that all amounts due and payable as defined in Appendix A have been paid as of the date of this Amendment.

  

	3.	Except for the terms and conductions set forth above, all terms of the Agreement shall remain in full force and effect 

IN WITNESS WHEREOF, the parties have executed this Amendment 1 as of the date first above written. 

 

									
	RIKEN GENESIS CO., LTD.	 		 	Oxford Immunotec Limited
					
	By:	 	 /s/ Yusuke Tsukahara
	 		 	By:	 	 /s/ Dr. Peter Wrighton-Smith

	Name:	 	 Yusuke Tsukahara
	 		 	Name:	 	 Dr. Peter Wrighton-Smith

	Title:	 	 CEO
	 		 	Title:	 	 CEO

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 APPENDIX A (Effective as of July 1st, 2012) 

DMAH Service Package for in-Vitro Diagnostics 
 We
(MAH) support marketing in Japan for the PRODUCTS placed on the market by the foreign manufacturer. 
 We must act as the foreign manufacturer’s
contact point for all Japanese Authorities. 
 We oversee the GQP and will be in charge of monitoring the shipping and receiving methods of the foreign
manufacturer. 
  

	 	•	 	We are responsible for notifying the PMDA of any manufacturing or in-process control changes. 

  

	 	•	 	We communicate with your DISTRIBUTOR and create the Import Procedure for your DISTRIBUTOR. 

 We
communicate with your packaging manufacturer to develop the Quality Agreement and assist in preparation of the Manufacturing Standard (Seihinhvojunsho) for labeling and warehousing as applicable. 

We are responsible for establishing and ensuring the release criteria and Quality Standard (Hinshitsuhyojunsyo) for each PRODUCT. 

 

	 	•	 	We prepare and submit the Import Submission for each PRODUCT family for customs clearance. 

 We register
JAN code to MEDIS for each item of the PRODUCTS. 
  

	 	•	 	We are responsible for handling all necessary communication between foreign manufacturer and MHLW in the case of a PRODUCT recall. 

We protect the confidentiality of your documentation. The Japanese Authorities are the only entities to whom we will show the documents, and only upon their
request. 
  

	 	•	 	We obtain your PAL certificates and other documentation for each PRODUCT from the Japanese Authorities and forward them to you. We will ensure that all certificates and approvals will be issued in your
(MANUFACTURER’s) name. 

  

	 	•	 	We have right to conduct audits of your facilities. The MAH must be able to show their audit records of the foreign manufacturer which has no location in Japan to Japanese Authorities upon request. If your company faces
a serious or many reportable events, this will be expected. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Fee Structure 

One time initiation fee of JPY 200,000 upon signing of this Agreement. This includes the fee for review of IVD documentation, labeling, and developing the
required Quality Standard (Hinshitsuhyojunsyo) and Import Submission, Quality Agreement, JAN Code registration. An additional one-time [***] fee per a PRODUCT family is required for an additional PRODUCT family. This also includes the review of IVO
documentation, labeling, and developing the required Quality Standard (Hinshitsuhyojunsyo) and Import Submission. 
 DMAH Retainer and Handling Fee: 

We charge a monthly retainer handling fee and commission per commercial invoice at custom clearance for PRODUCTS listed in APPENDIX B (collectively the
“Monthly Fee”) 
 We offer the following three Monthly Fee options. OPTION 1: 

JPY 150,000 per month plus [***] commission applied to each commercial invoice for a PRODUCT listed in APPENDIX B, invoiced monthly. 

OPTION 2: 
 JPY 100,000 per month plus [***] commission applied
to each commercial invoice for a PRODUCT listed in APPENDIX B, invoiced monthly. 
 OPTION 3 (In case the PRODUCTS are delivered directly to DISTRIBUTOR by
MANUFACTURER): 
 JPY 150,000 per month plus [***] commission applied to each commercial invoice for a PRODUCT list APPENDIX B. The [***] will be charged
monthly and the commission of [***] will be charged per shipment. 
 Note: 

Once you have reached [***] in total fees paid to MAH for the current calendar year, MAH will waive the Monthly Fee going forward for the remainder of the
calendar year (except as set forth in the next succeeding bullet point). 
 However, if the total invoiced amount for the year cleared through customs
reaches [***], MAH will charge a [***] commission on the invoiced amount in excess of the [***], in addition to the already charged [***]. 
 To set-up
Import Procedure for shipping process, [***] is charged per DISTRIBUTOR, if any. This includes necessary communication with the DISTRIBUTOR including explanation of new import procedure. 

If necessary, vigilance/reportable event reporting will be charged on an hourly rate basis of [***]. 

If an on-site audit of your facilities is required, fees will be charged at the rate of [***] per person per day, with a fee cap of [***] (2 persons for 2
days). In addition, Manufacturer will reimburse MAH for reasonable out-of-pocket travel expenses of the auditing team, at cost (without mark-up), with all air travel in economy class and accommodations at standard business (not luxury) hotels. MAH
will endeavour to use audit personnel who are geographically proximate to the facility to be audited. In the event the on-site audit cannot be completed by two persons in two days (or by one person in four days), the parties agree to discuss
appropriate adjustments to the fee cap. 
 Travel expenses where applicable are charged at cost. 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	•	 	Manufacturer is responsible for payment of all fees related to the Product registration charged by the PMDA or Registration Certification Body. 

The amount of fees for custom clearances including consumption taxes to be paid at customs clearance which must be paid to MAH before customs clearance can
occur. We will invoice the amount of fees to your DISTRIBUTOR as a substantial importer and not release PRODUCT to your DISTRIBUTOR until paid. 
  

	 	•	 	If RIKEN GENESIS is assuming the DMAH role for any Product from the MANUFACTURER’s existing MAH/DMAH, RIKEN GENESIS must gather the following information and perform the additional actions itemized below. Our
assistance with the following activities will be billed at a fee of [***] per hour, plus travel time and travel expenses, which are invoiced at cost: 

  

	 	•	 	Obtain the GQP and GVP, including quality control records, release judgment records and adverse event/field corrective action records, complaint data, et al. 

 

	 	•	 	Succeed original copy of the Pre-Market Approval/Certification (PMA/PMC) and copy of the application of the Pre-Market Approval/Certification (PMA/PMC) 

 

	 	•	 	Succeed copy of package insert, instruction for use/operation manual and labeling 

  

	 	•	 	Prepare and submit DMAH Change Notification 

 Notes: 

 

	 	•	 	In Japan, class I IVDs are not required to go through the Pre-market Approval or Pre-market Certification process. Instead, registration is executed by the Pre-market Submission process with no assessment by the PMDA or
a registered Certification Body as is required with a Premarket Approval or Pre-market Certification. 

  

	 	•	 	While the Foreign Special Approval System under the PAL is not applicable for PRODUCTS that fall under the Pre-market Submission process, you can select MAH as your MAH rather than as your DMAH. 

 

	 	•	 	Manufacturer must appoint a licensed Packaging Manufacturer, Distribution Company and if necessary a Logistics Firm licensed for your specific PRODUCTS. 

 

	 	•	 	In the case of a transfer of existing registered PRODUCTS from your existing MAH or DMAH, MANUFACTURER is responsible for providing all of the documents, e.g., pre-market approval application, package insert, Quality
Standard (Hinshitsuhyojunsyo) etc., needed to transfer from the existing MAH or DMAH. Any fee and/or costs for re-registration of the PRODUCTS transferred from the existing MAH or DMAH will be charged separately.EX-10.1

 Exhibit 10.1 

EXECUTION COPY 
 AMENDMENT
NO. 1 
 Dated as of November 5, 2013 

to 
 AMENDED AND RESTATED CREDIT
AGREEMENT 
 Dated as of September 26, 2013 

THIS AMENDMENT NO. 1 (this “Amendment”) is made as of November 5, 2013 by and among M/A-COM Technology Solutions
Holdings, Inc., a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), under
that certain Amended and Restated Credit Agreement dated as of September 26, 2013 by and among the Borrower, the Lenders and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to time, the
“Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement. 

WHEREAS, the Borrower has requested that the requisite Lenders and the Administrative Agent agree to certain amendments to the Credit
Agreement; 
 WHEREAS, the Borrower, the Lenders party hereto and the Administrative Agent have so agreed on the terms and conditions set
forth herein; 
 NOW, THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Lenders party hereto and the Administrative Agent hereby agree to enter into this Amendment. 

1. Amendments to the Credit Agreement. Effective as of the date of satisfaction of the conditions precedent set forth in
Section 2 below, the parties hereto agree that the Credit Agreement is hereby amended as follows: 
 (a) Section 6.01
of the Credit Agreement is hereby amended to (x) delete the word “and” appearing at the end of clause (n) thereof, (y) delete the period at the end of clause (o) thereof and replace such period with “; and”
and (z) insert the following as a new clause (p) thereof: 
 “(p) Indebtedness of any Person that becomes a
Subsidiary after the date hereof pursuant to the acquisition by the Borrower of Mindspeed Technologies, Inc., a Delaware corporation (“Target”); provided that (i) such Indebtedness exists at the time such Person becomes
a Subsidiary and is not created in contemplation of or in connection with such Person becoming a Subsidiary (provided that additional Indebtedness created as a result of the acquisition of Target by operation of make-whole premiums, conversion
rights and the like pursuant to and in accordance with such existing Indebtedness, but subject to the limitation set forth in clause (ii) below, shall not be prohibited by this clause (i)) and (ii) the aggregate principal amount of
Indebtedness permitted by this clause (p) shall not exceed $60,000,000 at any time outstanding; 

 (b) Section 6.01(h) of the Credit Agreement is hereby amended and restated in its
entirety to read as follows: 
 “(h) Permitted Qualifying Indebtedness in an aggregate principal amount not to exceed,
when taken together with the aggregate principal amount of Indebtedness permitted by clause (p) below, $100,000,000 at any time outstanding;” 

2. Conditions of Effectiveness. The effectiveness of this Amendment is subject to the conditions precedent that (i) the
Administrative Agent shall have received counterparts of this Amendment duly executed by the Borrower, the Required Lenders and the Administrative Agent, (ii) the Administrative Agent shall have received counterparts of the Consent and
Reaffirmation attached as Exhibit A hereto duly executed by the Subsidiary Guarantors and (iii) the Administrative Agent shall have received payment and/or reimbursement of the Administrative Agent’s and its affiliates’
reasonable and documented fees and expenses (including, to the extent invoiced, reasonable and documented fees and expenses of counsel for the Administrative Agent) in connection with this Amendment. 

3. Representations and Warranties of the Borrower. The Borrower hereby represents and warrants as follows: 

(a) This Amendment and the Credit Agreement as modified hereby constitute legal, valid and binding obligations of the Borrower and are
enforceable against the Borrower in accordance with their terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity,
regardless of whether considered in a proceeding in equity or at law. 
 (b) As of the date hereof and after giving effect to the terms of
this Amendment, (i) no Default or Event of Default shall have occurred and be continuing and (ii) the representations and warranties of the Borrower set forth in the Credit Agreement, as amended hereby, are true and correct in all material
respects (or, in the case of any representation or warranty expressly qualified by materiality or Material Adverse Effect, in all respects), except to the extent the same expressly relate to an earlier date in which case such representations and
warranties are true and correct in all material respects as of such earlier date. 
 4. Reference to and Effect on the Credit
Agreement. 
 (a) Upon the effectiveness hereof, each reference to the Credit Agreement in the Credit Agreement or any other Loan
Document shall mean and be a reference to the Credit Agreement as amended hereby. 
 (b) Each Loan Document and all other documents,
instruments and agreements executed and/or delivered in connection therewith shall remain in full force and effect and are hereby ratified and confirmed. 

(c) Except with respect to the subject matter hereof, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver
of any right, power or remedy of the Administrative Agent or the Lenders, nor constitute a waiver of any provision of the Credit Agreement, the Loan Documents or any other documents, instruments and agreements executed and/or delivered in connection
therewith. 
 (d) This Amendment is a “Loan Document” under (and as defined in) the Credit Agreement. 

  
 2 

 5. Governing Law. This Amendment shall be construed in accordance with and governed by the
law of the State of New York. 
 6. Headings. Section headings in this Amendment are included herein for convenience of reference only
and shall not constitute a part of this Amendment for any other purpose. 
 7. Counterparts. This Amendment may be executed by one or
more of the parties hereto on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Signatures delivered by facsimile or PDF shall have the same force and effect
as manual signatures delivered in person. 
 [Signature Pages Follow] 

  
 3 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above
written. 
  

			
	 M/A-COM TECHNOLOGY SOLUTIONS

HOLDINGS, INC.,

as the Borrower

		
	By:	 	 /s/ Conrad Gagnon

	 Name: Conrad Gagnon

Title: Chief Financial Officer

 Signature Page to Amendment No. 1 to 

Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	 JPMORGAN CHASE BANK, N.A.,

individually as a Lender, as the Swingline Lender, as the Issuing Bank and as Administrative Agent

		
	 By:
	 	 /s/ Justin Kelley

	 Name: Justin Kelley

Title: Vice President

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	HSBC BANK USA, NATIONAL ASSOCIATION, as a Lender
		
	 By:
	 	 /s/ Lynn R. Schade

	 Name: Lynn R. Schade

Title: Vice President

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

			
	 BANK OF AMERICA, N.A.,

as a Lender

		
	 By:
	 	 /s/ Thomas C. Lillis

	 Name: Thomas C. Lillis

Title: Senior Vice President

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	TD BANK, N.A., individually as a Lender and as a Co-Documentation Agent
		
	By:	 	 /s/ Amy LeBlanc Hackett

	Name: Amy LeBlanc Hackett
	Title: SVP

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	 BARCLAYS BANK PLC,
 as a
Lender

		
	By:	 	 /s/ Noam Azachi

	Name: Noam Azachi
	Title: Vice President

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	 FIRST NIAGARA BANK, N.A.,
 as a
Lender

		
	By:	 	 /s/ Robert Dellatorre

	Name: Robert Dellatorre
	Title: Vice President

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	 GOLDMAN SACHS BANK USA,
 as a
Lender

		
	By:	 	 /s/ Lauren Havens

	Name: Lauren Havens
	Title: Authorized Signatory

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 
			
	 RAYMOND JAMES BANK, N.A.,
 as a
Lender

		
	By:	 	 /s/ Kathy Bennett

	Name: Kathy Bennett
	Title: VP

  
 Signature Page to
Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc. 

 EXHIBIT A 

Consent and Reaffirmation 

Each of the undersigned hereby acknowledges receipt of a copy of the foregoing Amendment No. 1 to Amended and Restated Credit Agreement
with respect to that certain Amended and Restated Credit Agreement dated as of September 26, 2013 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among
M/A-COM Technology Solutions Holdings, Inc., a Delaware corporation (the “Borrower”), the Lenders and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), which Amendment No. 1 to
Amended and Restated Credit Agreement is dated as of November 5, 2013 and is by and among the Borrower, the financial institutions listed on the signature pages thereof and the Administrative Agent (the “Amendment”).
Capitalized terms used in this Consent and Reaffirmation and not defined herein shall have the meanings given to them in the Credit Agreement. Without in any way establishing a course of dealing by the Administrative Agent or any Lender, each of the
undersigned consents to the Amendment and reaffirms the terms and conditions of the Subsidiary Guaranty and any other Loan Document executed by it and acknowledges and agrees that the Subsidiary Guaranty and each and every such Loan Document
executed by the undersigned in connection with the Credit Agreement remains in full force and effect and is hereby reaffirmed, ratified and confirmed. All references to the Credit Agreement contained in the
above-referenced documents shall be a reference to the Credit Agreement as so modified by the Amendment and as the same may from time to time hereafter be amended, modified or restated. 

Dated November 5, 2013 
 [Signature Page
Follows] 

 IN WITNESS WHEREOF, this Consent and Reaffirmation has been duly executed as of the day and year
above written. 
  

			
	 M/A-COM TECHNOLOGY SOLUTIONS INC.

		
	By:	 	 /s/ Conrad Gagnon

	Name: Conrad Gagnon
	Title: Chief Financial Officer

  
 Signature Page to Consent
and Reaffirmation Amendment No. 1 to 
 Amended and Restated Credit Agreement dated as of September 26, 2013 

M/A-COM Technology Solutions Holdings, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]